Go Pro
→ MILLIONAIRE MASTERCLASS INVITE: Altucher (From Paradigm Press) (Ad)tc pixel Free STAB Stock Alerts

Statera Biopharma (STAB) Competitors

Statera Biopharma logo
$0.0001 0.00 (0.00%)
As of 09/23/2026 03:23 PM Eastern
Compare

STAB vs. ADTX, CMRA, EVLO, CALA, and EFTR

Should you buy Statera Biopharma stock or one of its competitors? Statera Biopharma's main competitors and comparable companies include Aditxt (ADTX), Comera Life Sciences (CMRA), Evelo Biosciences (EVLO), Calithera Biosciences (CALA), and eFFECTOR Therapeutics (EFTR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Statera Biopharma compare to Aditxt?

Statera Biopharma (NASDAQ:STAB) and Aditxt (NASDAQ:ADTX) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, risk, earnings, media sentiment, profitability, valuation and dividends.

In the previous week, Aditxt had 2 more articles in the media than Statera Biopharma. MarketBeat recorded 2 mentions for Aditxt and 0 mentions for Statera Biopharma. Statera Biopharma's average media sentiment score of 0.00 beat Aditxt's score of -0.51 indicating that Statera Biopharma is being referred to more favorably in the media.

Company Overall Sentiment
Statera Biopharma Neutral
Aditxt Negative

Statera Biopharma has higher earnings, but lower revenue than Aditxt.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Statera BiopharmaN/AN/AN/AN/AN/A
Aditxt$14.34K0.26-$41.71M-$100.79 thousandN/A

Statera Biopharma has a beta of 0.1, suggesting that its share price is 90% less volatile than the broader market. Comparatively, Aditxt has a beta of 1.21, suggesting that its share price is 21% more volatile than the broader market.

15.5% of Aditxt shares are owned by institutional investors. 5.5% of Statera Biopharma shares are owned by company insiders. Comparatively, 0.0% of Aditxt shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Statera Biopharma
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Aditxt
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Statera Biopharma has a net margin of 0.00% compared to Aditxt's net margin of -360,152.50%. Statera Biopharma's return on equity of 0.00% beat Aditxt's return on equity.

Company Net Margins Return on Equity Return on Assets
Statera BiopharmaN/A N/A N/A
Aditxt -360,152.50%-374.60%-105.93%

Summary

Aditxt beats Statera Biopharma on 6 of the 11 factors compared between the two stocks.

How does Statera Biopharma compare to Comera Life Sciences?

Comera Life Sciences (NASDAQ:CMRA) and Statera Biopharma (NASDAQ:STAB) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, institutional ownership, earnings, media sentiment, valuation, risk and analyst recommendations.

Company Net Margins Return on Equity Return on Assets
Comera Life SciencesN/A N/A N/A
Statera Biopharma N/A N/A N/A

Comera Life Sciences has a beta of 1.05, suggesting that its share price is 5% more volatile than the broader market. Comparatively, Statera Biopharma has a beta of 0.1, suggesting that its share price is 90% less volatile than the broader market.

In the previous week, Comera Life Sciences' average media sentiment score of 0.00 equaled Statera Biopharma'saverage media sentiment score.

Company Overall Sentiment
Comera Life Sciences Neutral
Statera Biopharma Neutral

Statera Biopharma has lower revenue, but higher earnings than Comera Life Sciences.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Comera Life Sciences$1.00M0.00-$18M-$0.18N/A
Statera BiopharmaN/AN/AN/AN/AN/A

Summary

Comera Life Sciences beats Statera Biopharma on 3 of the 3 factors compared between the two stocks.

How does Statera Biopharma compare to Evelo Biosciences?

Statera Biopharma (NASDAQ:STAB) and Evelo Biosciences (NASDAQ:EVLO) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, profitability, institutional ownership, earnings, risk, valuation, analyst recommendations and dividends.

0.3% of Evelo Biosciences shares are owned by institutional investors. 5.5% of Statera Biopharma shares are owned by company insiders. Comparatively, 1.0% of Evelo Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Statera BiopharmaN/AN/AN/AN/AN/A
Evelo BiosciencesN/AN/A-$114.53M-$4.21N/A

Company Net Margins Return on Equity Return on Assets
Statera BiopharmaN/A N/A N/A
Evelo Biosciences N/A N/A N/A

Statera Biopharma has a beta of 0.1, meaning that its share price is 90% less volatile than the broader market. Comparatively, Evelo Biosciences has a beta of 1.5, meaning that its share price is 50% more volatile than the broader market.

In the previous week, Statera Biopharma's average media sentiment score of 0.00 equaled Evelo Biosciences'average media sentiment score.

Company Overall Sentiment
Statera Biopharma Neutral
Evelo Biosciences Neutral

Summary

Evelo Biosciences beats Statera Biopharma on 3 of the 4 factors compared between the two stocks.

How does Statera Biopharma compare to Calithera Biosciences?

Calithera Biosciences (NASDAQ:CALA) and Statera Biopharma (NASDAQ:STAB) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, media sentiment, valuation, earnings, institutional ownership, analyst recommendations and dividends.

Calithera Biosciences has a beta of -1.26, meaning that its share price is 226% less volatile than the broader market. Comparatively, Statera Biopharma has a beta of 0.1, meaning that its share price is 90% less volatile than the broader market.

In the previous week, Calithera Biosciences had 1 more articles in the media than Statera Biopharma. MarketBeat recorded 1 mentions for Calithera Biosciences and 0 mentions for Statera Biopharma. Calithera Biosciences' average media sentiment score of 0.00 equaled Statera Biopharma'saverage media sentiment score.

Company Overall Sentiment
Calithera Biosciences Neutral
Statera Biopharma Neutral

Company Net Margins Return on Equity Return on Assets
Calithera BiosciencesN/A N/A N/A
Statera Biopharma N/A N/A N/A

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Calithera BiosciencesN/AN/A-$39.65MN/AN/A
Statera BiopharmaN/AN/AN/AN/AN/A

Summary

Calithera Biosciences beats Statera Biopharma on 2 of the 3 factors compared between the two stocks.

How does Statera Biopharma compare to eFFECTOR Therapeutics?

eFFECTOR Therapeutics (NASDAQ:EFTR) and Statera Biopharma (NASDAQ:STAB) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, media sentiment, risk, institutional ownership, profitability, analyst recommendations, valuation and dividends.

eFFECTOR Therapeutics has a beta of 2.48, suggesting that its stock price is 148% more volatile than the broader market. Comparatively, Statera Biopharma has a beta of 0.1, suggesting that its stock price is 90% less volatile than the broader market.

Company Net Margins Return on Equity Return on Assets
eFFECTOR TherapeuticsN/A N/A N/A
Statera Biopharma N/A N/A N/A

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
eFFECTOR TherapeuticsN/AN/A-$35.81M-$13.08N/A
Statera BiopharmaN/AN/AN/AN/AN/A

In the previous week, eFFECTOR Therapeutics' average media sentiment score of 0.00 equaled Statera Biopharma'saverage media sentiment score.

Company Overall Sentiment
eFFECTOR Therapeutics Neutral
Statera Biopharma Neutral

57.7% of eFFECTOR Therapeutics shares are held by institutional investors. 4.7% of eFFECTOR Therapeutics shares are held by company insiders. Comparatively, 5.5% of Statera Biopharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

eFFECTOR Therapeutics beats Statera Biopharma on 3 of the 4 factors compared between the two stocks.

Get Statera Biopharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for STAB and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding STAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

STAB vs. The Competition

Export
MetricStatera BiopharmaPharmaceuticals IndustryHealthcare SectorNASDAQ Exchange
Market Cap$1K$12.53B$7.26B$13.10B
Dividend YieldN/A2.63%2.52%12.57%
P/E Ratio0.00792.39274.9825.77
Price / SalesN/A850.84679.2597.61
Price / CashN/A88.6477.8052.76
Price / BookN/A10.6910.526.34
Net IncomeN/A$2.83B$3.49B$360.00M
7 Day PerformanceN/A-0.69%-1.08%-0.11%
1 Month PerformanceN/A-1.10%-3.39%-3.42%
1 Year PerformanceN/A2.10%15.08%5.46%

Statera Biopharma Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
STAB
Statera Biopharma
N/A$0.00
flat		N/A-50.0%$1KN/AN/A46
ADTX
Aditxt
0.1508 of 5 stars		$0.00
-6.5%		N/A-100.0%$4K$14.34KN/A60
CMRA
Comera Life Sciences
N/AN/AN/AN/A$3K$1.00MN/A2
EVLO
Evelo Biosciences
N/AN/AN/A-80.0%$2KN/AN/A66
CALA
Calithera Biosciences
N/A$0.00
flat		N/A+200.0%$1KN/AN/A60

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:STAB) was last updated on 9/24/2026 by MarketBeat.com Staff.
From Our Partners
A letter from Shannon Stansberry
Porter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...
Porter & Company | Sponsoredtc pixel
Shocking new footage just released
Gerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he ...
Digest Publishing | Sponsoredtc pixel
Your book attached
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...
Profits Run | Sponsoredtc pixel
NASA's ISS Replacement Could Go to This Tiny Space Firm
NASA has commissioned SpaceX to decommission the $150 billion International Space Station, but the contract to...
Behind the Markets | Sponsoredtc pixel
Analyst nicknamed “The Prophet” issues new warning for America
Whitney Tilson exposed a major company on 60 Minutes in an Emmy-winning investigation - the stock lost nearly ...
Stansberry Research | Sponsoredtc pixel
The retirement stock I'd buy before Nvidia today
In 2014, Marc Chaikin pointed readers toward Nvidia. Now the 60-year Wall Street veteran and creator of the Ch...
Chaikin Analytics | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
These gold assets are priced for $1,800 gold [it's over $4,000]
Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...
Golden Portfolio | Sponsoredtc pixel